Full Text Journal Articles by
Author Marc Pliskin

Advertisement

Find full text journal articles








Reply by Authors.

Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Marc Pliskin, J Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Nicholas N Tadros, Steven N Gange, Claus G Roehrborn,

J Urol (The Journal of urology)
[2021, :101097JU000000000000177803]

Cited: 0 times

View full text PDF listing >>



Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Kevin T McVary, Marc C Gittelman, Kenneth A Goldberg, Kalpesh Patel, Neal D Shore, Richard M Levin, Marc Pliskin, J Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett E Cowan, Christopher H Cantrill, Lance A Mynderse, James C Ulchaker, Nicholas N Tadros, Steven N Gange, Claus G Roehrborn,

<h4>Purpose</h4>We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia.<h4>Materials and methods</h4>A total of 197 subjects <u>></u>50 years of age with International Prostate Symptom Score ≥13, maximum flow ... Read more >>

J Urol (The Journal of urology)
[2021, :101097JU0000000000001778]

Cited: 0 times

View full text PDF listing >>



Advertisement

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Neal D Shore, Fred Saad, Michael S Cookson, Daniel J George, Daniel R Saltzstein, Ronald Tutrone, Hideyuki Akaza, Alberto Bossi, David F van Veenhuyzen, Bryan Selby, Xiaolin Fan, Vicky Kang, Jackie Walling, Bertrand Tombal, ,

<h4>Background</h4>Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.<h4>Methods</h4>In this phase ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 382(23):2187-2196]

Cited: 19 times

View full text PDF listing >>



Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R Smith, ,

<h4>Background</h4>Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.<h4>Methods</h4>We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer ... Read more >>

N Engl J Med (The New England journal of medicine)
[2019, 380(13):1235-1246]

Cited: 110 times

View full text PDF listing >>





Advertisement

Disclaimer
0.8134 s